Heart disease risk higher for women who have these unhealthy lifestyle habits
Eight specific habits — diet, sleep, physical activity, smoking, body mass index, blood glucose, lipids and blood pressure — appear to have twice the impact on heart health risk for women compared to men, found researchers at Sunnybrook Health Sciences Centre in Toronto.
The findings will be presented at the American College of Cardiology's Annual Scientific Session in Chicago on March 29-31, 2025.
Cannabis Use Endangers Heart Health For Certain Group
The study included data from over 175,000 Canadian adults without existing heart conditions who enrolled in the Ontario Health Study between 2009 and 2017, according to a press release.
The researchers analyzed the participants' scores for the eight risk factors and then tracked the incidence of seven heart disease outcomes over an 11-year period.
Read On The Fox News App
Those outcomes included heart attack, stroke, unstable angina (chest pain that results from restricted blood flow to the heart), peripheral arterial disease (narrowed blood vessels in the arms or legs), heart failure and coronary revascularization (procedures to open blocked arteries) and cardiovascular death, the release stated.
Heart Disease Could Be Prevented With This One Simple Test
Overall, more women were found to have ideal health (9.1% compared to 4.8% of men).
They were also less likely to have poor health (21.9% compared to 30.5% of men).
Women who had poor health, however, were shown to have nearly five times the risk of heart disease than women with ideal health, the study found.
In comparison, men with poor health had 2.5 times the risk of heart disease compared to men with ideal health.
Among women with intermediate health, there was a 2.3 times higher risk than for those with ideal health, compared to 1.6 times the risk for men with intermediate health.
"For the same level of health, our study shows that the increase in risk [related to each factor] is higher in women than in men — it's not one-size-fits-all," said lead author Maneesh Sud, M.D., Ph.D., assistant professor in the department of medicine, interventional cardiologist and clinician scientist at Sunnybrook Health Sciences Centre in Toronto, in the release.
"We found that women tend to have better health than men, but the impact on outcomes is different. The combination of these factors has a bigger impact in women than it does in men."
This Disease Kills More People Than All Cancers And Accidents Combined
This is a new finding that hasn't been seen in other studies, the researcher added.
Based on the study findings, the researchers concluded that "sex-specific screening or risk assessment approaches" could more accurately predict people's heart disease risk.
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News' senior medical analyst, was not involved in the study, but shared his insights on the possible reasons for the findings.
"I think the reason women are being found to be more susceptible to heart disease is because of particular milestone stresses in their lives that men don't share, which include dramatic hormonal shifts that can bear directly on cardiac function," he told Fox News Digital.
Those milestones may include pregnancy, childbirth and menopause, the doctor noted.
"Keep in mind that estrogen is in some respects cardio-protective, and it drops dramatically with menopause," Siegel said. "And at the same time, cholesterol (a cardiac risk factor) increases, as may weight."
"Overall, women tended to have better health than men, with better diets, blood sugar, cholesterol and blood pressure, but those in intermediate health had a higher risk of heart problems," he went on.
Due to the study's limited population, "only certain conclusions can be drawn," Siegel added.
Click Here To Sign Up For Our Health Newsletter
Dr. Bradley Serwer, a Maryland-based cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals nationwide, said there has been a need for studies specifically designed to focus on women's cardiovascular risk.
"For many years, we have falsely assumed that traditional cardiovascular risk factors affected populations similarly," Serwer, who was not involved in the study, told Fox News Digital.
"We know that premenopausal women have a lower age-adjusted cardiovascular risk, but this catches up after menopause."
For more Health articles, visit www.foxnews.com/health
More research is needed to understand the underlying reasons for this phenomenon, the cardiologist noted.
"Is it solely attributable to the protective effects of estrogen, or are there other unrecognized contributors? I commend the authors of this study for their contributions, as they further challenge our conventional approaches to primary prevention in women."Original article source: Heart disease risk higher for women who have these unhealthy lifestyle habits
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
MDpanel Expands Internationally Through Strategic Combination with Integra Medical Consulting
LOS ANGELES, July 29, 2025 /PRNewswire/ -- MDpanel is happy to announce a strategic combination with Integra Medical Consulting (Integra), a highly respected independent medical evaluation (IME) provider based in Vancouver, British Columbia. This milestone marks MDpanel's second expansion within Canada, but the first conducting full IMEs. It represents a significant step forward in MDpanel's mission to elevate access to high-quality medical opinions across North America. For almost a decade, Integra has built a strong reputation in Canada for its expert medical professional network, commitment to objectivity, and high-touch service model. By partnering with Integra, MDpanel deepens its reach into the Canadian market while remaining focused on delivering timely, objective, and high-quality medical opinions. "We are thrilled to partner with the Integra team," said MDpanel CEO, Jason Erdell. "This collaboration allows us to bring our platform and processes to a new geography, while learning from a well-established team that shares our values around physician excellence and client service." The partnership will allow both organizations to combine resources to better serve government agencies, solicitors, insurers, and employers. Together, MDpanel and Integra will continue to invest in report quality, operational scale, and client experience while preserving the local relationships and trusted expertise that define Integra's presence in Canada. "Partnering with MDpanel gives us access to tools and infrastructure that will help us grow responsibly and continue to provide the standard of service our clients and medical professionals have come to expect," Integra CEO Erica Enstrom said. MDpanel continues to build a national — and now international — network of high-performing medical professionals. With the addition of Integra, MDpanel is uniquely positioned to support clients who demand a consistent, technology-enabled experience backed by clinical credibility. Integra's vast physician network will soon be able to access the industry's only end-to-end platform within which they can entirely produce medical opinions with support not otherwise attainable by traditional hands-off approaches. Calfee, Halter & Griswold LLP and Cassels Brock & Blackwell LLP served as legal advisors to MDpanel. TechStrat served as the exclusive M&A advisor to Integra. About MDpanelMDpanel is the leading provider of expert medical opinions in the United States, serving physicians across a range of specialties. MDpanel is committed to being the partner of choice for physicians, carriers, attorneys and injured workers by connecting those in need of medical opinions with the most qualified and highly regarded medical professionals. For more information about MDpanel, please visit Media ContactDavid LiaoVP of Corporate View original content to download multimedia: SOURCE MDpanel
Business Wire
19 minutes ago
- Business Wire
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. ('IPA', 'Company', 'we' or 'us') (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. We delivered strong annual and record fourth quarter revenues, significantly improved gross margins, and achieved one of our strongest adjusted EBITDA performances in the Company's history, with a loss of only $316,000. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180% in Fiscal year 2025 and had gross margins approaching 90% BioStrand currently represents over 5% of total annual revenue this year, up from less than 2% in Fiscal Year 2024 Recent Corporate Highlights: The Company's LENS ai ™ platform demonstrated that it's in silico epitope mapping achieves results on previously unseen antibody–antigen complexes with results that are on par with gold-standard X-ray crystallography—yet delivering structural insights in hours instead of weeks. An important breakthrough using the Company's HYFT®-powered LENS ai platform, as it identified a highly conserved epitope across all four dengue virus serotypes, a key milestone toward developing a potential universal dengue vaccine. Subsequently announced in silico data supporting the vaccine candidate's safety and its ability to activate a balanced immune response. IPA's AI-designed GLP-1 peptides outperformed or matched semaglutide in independent receptor activation studies, further validating the Company's HYFT-driven LENS ai platform. Entered a strategic USD $8–10 million partnership with a publicly traded biotechnology company focused on the discovery and development of antibody-drug conjugates and bispecific antibodies for potential oncology therapeutics. Realigned internal R&D strategy to focus on launching an AI-powered therapeutic pipeline, reinforcing IPA's shift toward a bio-native AI drug discovery model. ImmunoPrecise subsidiary signed material transfer agreement with Biotheus (now BioNTech), for the transfer and evaluation of antibody assets for bispecific tumor-targeting. Successfully engineered antibodies in silico to a challenging tumor target using LENS ai, advancing IPA's vision for accessible, next-generation therapeutics. Appointed industry veteran Jon Lieber to its Board of Directors, bringing over 30 years of strategic leadership across biotech, capital markets, and public company governance, further strengthening IPA's financial oversight and commercial execution. Named Jeff Fried, a recognized healthcare data visionary, to its Advisory Board. Fried has played a key role in advancing IPA's AI platform capabilities, particularly the integration of vector search to support large-scale, AI-driven discovery within LENS ai ecosystem. Regained compliance with Nasdaq minimum bid price requirement, reflecting strengthened investor confidence and continued alignment with strategic listing standards. 'Fiscal 2025 was a record-setting year for IPA across multiple dimensions,' said Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO. 'We delivered strong annual and record fourth quarter revenues, significantly improved gross margins, and achieved one of our strongest adjusted EBITDA performances in the Company's history, with a loss of only $316,000. This reflects our continued progress toward profitability while accelerating innovation through our HYFT-powered LENS ai platform. Our BioStrand segment alone grew by more than 180% in Fiscal 2025, highlighting the strength of our AI-driven pipeline. These results underscore the growing commercial validation of our technology, our strategic collaborations, and our ability to deliver real-world impact through next-generation antibody discovery and therapeutic design.' 'As we look ahead to the next fiscal year, we are well-positioned to build on our momentum. We are poised to refocus our business on AI-based product development utilizing our LENS ai platform, powered by our patented HYFT technology. We anticipate the near-term completion of the previously announced divestiture of our Dutch subsidiary, as part of our continued focus on streamlining operations and aligning resources with strategic priorities. Together, these strategic steps will sharpen our focus, strengthen our core capabilities, and set the stage for an even brighter future for IPA,' concluded Dr. Bath. Fourth Quarter 2025 Financial Results Revenue for the three months ended April 30, 2025, was $7.0 million, representing an 8% increase compared to $6.5 million for the same period in 2024. Gross profit for the three months ended April 30, 2025, was $4.5 million, up from $3.1 million in the same period last year. Gross margin for FY25 rose sharply to 64%, compared to 48% for FY24. This improvement was driven, in part, by a greater contribution from high-margin BioStrand revenues. Research and development ('R&D') expenses totaled $1.1 million, down from $1.3 million in the prior-year quarter, due to reallocating project-related R&D efforts to cost of sales for clients. Sales and marketing expenses increased to $1.0 million, compared to $0.9 million in the same period last year, due to an increase in digital campaign expenses. General and administrative expenses declined to $3.7 million from $4.1 million, driven by ongoing cost control efforts. Operating loss, excluding amortization and non-recurring charges, improved significantly to $1.4 million, compared to $3.2 million in the fourth quarter of Fiscal Year 2024. Net loss narrowed to $2.2 million, a marked improvement from a net loss of $17.6 million in the same quarter last year, which included a $15 million non-cash impairment charge related to BioStrand's goodwill and intangible assets. Adjusted EBITDA loss improved to $0.3 million, compared to a loss of $1.7 million in the fourth quarter of Fiscal Year 2024, reflecting improved gross profits and enhanced operating efficiency. Full Year 2025 Financial Results Revenue for Fiscal Year 2025 was $24.5 million, up slightly (without rounding) from $24.5 million in Fiscal Year 2024. Gross Profit for Fiscal Year 2025 was $13.5 million, a 12.4% increase compared to $12.1 million in Fiscal Year 2024. Gross margin expanded by 600 basis points to 55%, up from 49% in the prior year. This margin improvement was driven by a greater revenue contribution from the high-margin BioStrand segment, coupled with an increased focus on cost efficiencies. Research and development expenses were $4.9 million in Fiscal Year 2025, up from $4.0 million in Fiscal Year 2024, reflecting increased investment in R&D activities within the BioStrand segment. Sales and marketing expenses were $4.3 million in Fiscal Year 2025, compared to $3.5 million in Fiscal Year 2024, reflecting increased spending on advertising related to digital campaign expenses. General and administrative expenses totaled $14.7 million in Fiscal Year 2025, down from $15.6 million in Fiscal Year 2024, reflecting the Company's continued focus on operational efficiency and cost discipline. Operating loss in Fiscal Year 2025, excluding amortization and non-recurring charges, improved to $10.4 million, compared to $11.1 million in Fiscal Year 2024. Net loss in Fiscal Year 2025 was $30.2 million, or $(0.91) per share on a basic and diluted basis, compared to a net loss of $26.1 million or $(1.02) on a basic and diluted basis in Fiscal Year 2024. Total cash, cash equivalents, and marketable securities, including restricted cash, were $10.8 million as of April 30, 2025. The reconciliation of Net Loss to Adjusted EBITDA is presented in the table below: *All financial figures are in Canadian Dollars (CAD) unless otherwise stated. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, July 29, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at ***Participant Dial-In Details*** Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toll-Free (800) 715-9871 ***Webcast Details*** Attendee URL: Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at and including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is an AI-driven biotherapeutic research, technology and scientifically robust life science company that discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures and innovative approaches to antibody discovery, development, and production. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. These statements reflect the Company's expectations, plans, projections, and beliefs regarding future events or performance. Words such as 'expects,' 'anticipates,' 'intends,' 'believes,' 'plans,' 'potential,' 'will,' 'may,' 'continue,' and variations thereof are intended to identify forward-looking statements. Forward-looking statements in this release include, but are not limited to, statements related to the Company's operational and financial outlook, the potential impact and continuity of strategic partnerships, including the recently announced commercial agreement and collaborations with cloud infrastructure providers, our projected growth in AI-driven revenues and margins, our ability to commercialize new technologies such as de novo antibody design and AI-designed GLP-1 therapeutics, future demand for our platform capabilities, ongoing strategic initiatives including business realignment and divestitures, and our ability to drive sustainable profitability. The Company uses certain non-IFRS financial measures as supplemental indicators of its financial and operating performance. These non-IFRS financial measures are adjusted EBITDA and adjusted operating expenses. The Company believes these supplementary financial measures reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. These non-IFRS measures do not have any standardized meaning prescribed under IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. The Company defines adjusted EBITDA as operating earnings before taxes, amortization, depreciation, accretion, asset impairment charges, foreign exchange gain/loss, interest and other income and share-based compensation. Adjusted EBITDA is presented on a basis consistent with the Company's internal management reports. The Company discloses adjusted EBITDA to capture the profitability of its business before the impact of items not considered in management's evaluation of operating unit performance. The most directly comparable IFRS measure to adjusted EBITDA is net loss. These statements are based on management's current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. These include, but are not limited to: execution risks related to strategic partnerships, delays or failures in technology development or commercialization, market adoption of AI-based drug discovery tools, fluctuations in financial markets, general economic conditions, and risks related to funding requirements and liquidity. The Company cautions readers not to place undue reliance on these forward-looking statements. All such statements are made as of the date of this release and, unless required by law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. For a complete discussion of risk factors, investors should refer to IPA's filings with Canadian and U.S. securities regulators, including the most recent Annual Report on Form 20-F available at and IMMUNOPRECISE ANTIBODIES LTD. (Unaudited - Expressed in Canadian dollars) (in thousands) April 30, 2025 $ April 30, 2024 $ ASSETS Current assets Cash 10,665 3,459 Amounts receivable, net 4,115 3,790 Tax receivable 143 414 Inventory 2,095 2,139 Unbilled revenue 548 277 Prepaid expenses 1,188 1,408 18,754 11,487 Restricted cash 126 86 Deposit on equipment 502 475 Property and equipment 15,762 16,696 Intangible assets 1,067 23,557 Goodwill 8,230 7,687 Total assets 44,441 59,988 LIABILITIES Current liabilities Accounts payable and accrued liabilities 5,283 4,372 Deferred revenue 1,090 1,352 Tax payable 475 553 Leases 1,850 1,563 Deferred acquisition payments 314 284 9,012 8,124 Leases 11,553 12,118 Deferred income tax liability 250 4,068 Total liabilities 20,815 24,310 SHAREHOLDERS' EQUITY Share capital 136,371 119,773 Contributed surplus 12,833 12,388 Accumulated other comprehensive income 3,216 2,077 Accumulated deficit (128,794 ) (98,560 ) 23,626 35,678 Total liabilities and shareholders' equity 44,441 59,988 Expand IMMUNOPRECISE ANTIBODIES LTD. CONSOLIDATED STATEMENTS OF CASH FLOWS For the year ended April 30, 2025 and 2024 (Unaudited - Expressed in Canadian dollars) (in thousands) 2025 $ 2024 $ Operating activities: Net loss for the period (30,234 ) (26,115 ) Items not affecting cash: Accretion 10 19 Amortization and depreciation 5,119 5,735 Asset impairment 21,184 15,031 Deferred income taxes (3,935 ) (1,773 ) Foreign exchange 622 15 Gain on investment (7 ) (2 ) Share-based expense 445 1,535 (6,796 ) (5,555 ) Changes in non-cash working capital related to operations: Amounts receivable (298 ) (601 ) Inventory 138 (102 ) Unbilled revenue (248 ) 360 Prepaid expenses 261 624 Accounts payable and accrued liabilities 827 983 Sales and income taxes payable and receivable 8 733 Deferred revenue (302 ) 374 Net cash used in operating activities (6,410 ) (3,184 ) Investing activities: Purchase of equipment (799 ) (1,397 ) Security deposit on leases — (141 ) Deferred acquisition payments — (146 ) Sale of QVQ Holdings BV shares — 121 Net cash used in investing activities (799 ) (1,563 ) Financing activities: Proceeds from share issuance, net of transaction costs 12,228 2,360 Proceeds from debenture 4,242 — Repayment of leases (1,577 ) (1,339 ) Net cash provided by financing activities 14,893 1,021 Increase (decrease) in cash during the period 7,684 (3,726 ) Foreign exchange (438 ) (1,095 ) Cash – beginning of the period 3,545 8,366 Cash – end of the period 10,791 3,545 Cash is comprised of: Cash 10,665 3,459 Restricted cash 126 86 10,791 3,545 Cash paid for interest — — Cash paid for income tax 2 — Expand
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Mole Mobile is coming to Hamilton on Aug. 3
The Mole Mobile is coming to Hamilton. Melanoma Canada recently announced that the Mole Mobile will set up at Fortinos at 65 Mall Rd. from 10 a.m. to 4 p.m. on Sunday, Aug. 3. According to the Mole Mobile webpage , the Mole Mobile is the first mobile skin cancer screening unit in Canada. The tour around the country features two Mole Mobiles providing Canadians access to dermatologists and screenings in Canadian cities where wait times drag despite the prevalence of skin cancer. According to the press release from Melanoma Canada, melanoma and skin cancer are one of the few cancers with rising incident rates in Canada and across the world. 'Skin cancers are the most common type of cancer diagnosed in men over 49 years of age and are among the most common cancers diagnosed in youth and young adults. If detected, early melanoma and skin cancers are largely treatable,' said the press release. Until October, the Mole Mobile tour is set to bring certified Canadian dermatologists to communities across British Columbia, Ontario, Quebec and Alberta. The tour will also be stopping in Fort Erie, Niagara Falls and St. Catharines on July 31, Aug. 1 and Aug. 2, respectively. For more information on the Fort Erie, Niagara Falls and St. Catharines Mole Mobile cancer screening stops and other Ontario stops, check out the project's website . Démar Grant is a reporter at The Hamilton Spectator. Reach him at dgrant@ . Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
